Table 3. General clinical characteristics of the obese and non-obese cohorts.
Characteristic | Obese subjects (n=584) | Non-obese subjects (n=1104) | P | Obese subjects | Non-obese subjects | ||||
NAFLD (n=202) | Non-NAFLD (n=382) | P | NAFLD (n=343) | Non-NAFLD (n=761) | P | ||||
Age, years | 42.39±12.60 | 42.22±12.52 | <0.001 | 44.76±31.13 | 44.83±12.96 | 0.559 | 40.35±11.87 | 40.83±12.19 | 0.516 |
Male/female | 218/327 | 487/656 | <0.001 | 106/96 | 223/159 | 0.142 | 127/216 | 256/505 | 0.554 |
BMI, kg/m2 | 24.11±3.51 | 23.99±3.33 | <0.001 | 27.56±2.49 | 27.56±2.35 | 0.736 | 21.97±2.01 | 22.12±1.97 | 0.224 |
ALT, U/L | 23.78±17.59 | 23.67±25.52 | <0.001 | 31.34±22.65 | 31.01±36.84 | 0.200 | 19.23±11.82 | 19.97±16.26 | 0.625 |
AST, U/L | 25.18±14.51 | 21.25±9.72 | <0.001 | 35.39±11.68 | 25.06±15.81 | 0.052 | 20.54±5.99 | 21.56±10.97 | 0.296 |
γ-GT, U/L | 24.95±20.91 | 25.46±27.33 | <0.001 | 31.79±23.68 | 35.46±36.72 | 0.635 | 20.54±17.49 | 20.48±19.48 | 0.933 |
Serum triglyceride, mmol/L | 1.39±1.11 | 1.31±1.03 | <0.001 | 1.74±1.29 | 1.68±1.43 | 0.587 | 1.68±0.91 | 1.13±0.68 | 0.479 |
Serum total cholesterol, mmol/L | 4.90±1.01 | 4.87±1.00 | <0.001 | 5.05±1.06 | 6.52±1.48 | 0.838 | 4.81±0.98 | 4.80±0.93 | 0.790 |
Serum LDL-C, mmol/L | 2.85±0.67 | 2.84±0.69 | <0.001 | 3.01±0.70 | 2.99±0.68 | 0.895 | 2.75±0.62 | 2.77±0.66 | 0.608 |
Fasting plasma glucose, mmol/L | 5.32±1.06 | 5.34±1.03 | <0.001 | 5.58±1.16 | 5.70±1.41 | 0.510 | 5.17±1.00 | 5.15±0.71 | 0.278 |
Serum FGF21, pg/ml | 293.07±258.03 | 303.42±291.79 | <0.001 | 361.35±306.29 | 366.63±311.56 | 0.924 | 244.70±205.25 | 267.57±269.94 | 0.605 |
Data are means±SD or counts. P: level of statistical significance with the Kruscal-Wallis non-parametric test.